Stockscreener 앱 받기
18.16
0.44%
0.02
시간 외 거래:
18.16
전일 마감가:
$18.18
열려 있는:
$18.39
하루 거래량:
175.22K
Relative Volume:
0.78
시가총액:
$1.07B
수익:
-
순이익/손실:
$-147.32M
주가수익비율:
-3.4438
EPS:
-5.2733
순현금흐름:
$-122.10M
1주 성능:
-1.35%
1개월 성능:
-7.78%
6개월 성능:
+41.50%
1년 성능:
+117.12%
1일 변동 폭
$18.13
$18.66
1주일 범위
$18.03
$18.90
52주 변동 폭
$7.5262
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
18.16 | 1.08B | 0 | -147.32M | -122.10M | -5.2733 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Guggenheim | Buy |
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
MPM BioImpact reports 8.8% stake in DBV Technologies (DBVT) - Stock Titan
Combined General Meeting of June 3, 2026 - The Manila Times
Adage insiders report 22,272,884 shares in DBV Technologies (NASDAQ: DBVT) - Stock Titan
Artisan Partners (DBVT) discloses 2,219,386 ADS; 3.7% stake reported - Stock Titan
Vivo Opportunity (DBVT) holds 2.36M ADSs — 4.0% ownership disclosed - Stock Titan
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq - The Manila Times
DBV Technologies (DBVT) grants 1.74M performance share units to CEO - Stock Titan
Invus affiliates disclose 17.998M DBV ordinary shares (DBVT) — 6.1% reported - Stock Titan
DBVT Stock Price, Quote & Chart | DBV TECHNOLOGIES SA-SPON ADR (NASDAQ:DBVT) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
DBV Technologies (DBVT) ramps Q1 2026 spending but extends cash runway - Stock Titan
DBV Technologies Reports First Quarter 2026 Financial Results - The Manila Times
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
DBV Technologies (NASDAQ: DBVT) director Philina Lee files initial Form 3 ownership - Stock Titan
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know - Zacks Investment Research
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Goldman Sachs Keeps Their Sell Rating on DBV Technologies SA – American (DBVT) - The Globe and Mail
Combined General Meeting of June 11, 2025 - NTB Kommunikasjon
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Stock Forum & Discussion - Yahoo! Finance Canada
DBV technologies S.A. (ADR) (DBV1.SG) Stock Major Holders - Yahoo! Finance Canada
DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday - Defense World
DBV technologies S.A. (ADR) (DBV1.SG) company profile and facts - Yahoo Finance UK
DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT) - Seeking Alpha
Guggenheim Reiterates “Buy” Rating for DBV Technologies (NASDAQ:DBVT) - Defense World
Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
DBV Technologies Reports Full Year 2025 Financial Results and Business Update - markets.businessinsider.com
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document - The Manila Times
DBV Technologies (NASDAQ: DBVT) deepens 2025 loss but funds runway into 2027 - Stock Titan
Peanut patch developer DBV says cash funds operations into Q2 2027 - Stock Titan
Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - The Manila Times
DLD Asset Management LP Makes New $250,000 Investment in DBV Technologies S.A. $DBVT - Defense World
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH) - The Globe and Mail
DBV Technologies to Participate in Upcoming March Investor Conferences - The Manila Times
Biotech DBV Technologies lines up back-to-back March investor events - Stock Titan
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 - ChartMill
Guggenheim Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT) - The Globe and Mail
DBV Technologies stock surges on new peanut patch trial data - Investing.com
Phase 3 VITESSE data highlighted by DBV Technologies (NASDAQ: DBVT) - Stock Titan
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies Highlights Additional Data from Successful - GlobeNewswire
DBV Technologies (DBVT) Projected to Post Earnings on Thursday - Defense World
European ADRs Were Flat As Biotech Names Took The Lead - Finimize
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dbv Technologies Adr 주식 (DBVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
1.49%
0.12%
자본화:
|
볼륨(24시간):